BTIG Raises Natera (NTRA) Price Target to $430

On October 27, 2026, BTIG raised its price target on Natera, Inc. (NTRA) to $430 from $320 while maintaining a Buy rating. This update comes in a research note on the same day, reflecting BTIG's confidence in the company's growth prospects.

Natera, Inc. focuses on developing and marketing molecular testing services. The company's offerings include tests for cancer monitoring and genetic screening, positioning it well in the healthcare diagnostics sector. The stock closed at $413.98 on October 27, 2026, but recently traded lower at $404.90, which is about 2.2% below the closing price. The new price target suggests that analysts see potential upside in the stock despite its current position.

NTRA Natera, Inc.

$410.82 ▲ +79.52% year to date

1M 3M YTD

Daily close · Oct 27, 2026

Other Institutional Activity in Natera, Inc.

Tokio Marine Asset Management holds 4,400 shares of Natera, valued at about $1.82 million. Duquesne Family Office LLC increased its stake by 122,845 shares, bringing its total to 3,186,306 shares worth approximately $1.29 billion. This activity highlights continued interest in Natera from institutional investors.

Natera, Inc. Stock Up 0.9%

Natera, Inc. trades near its recent closing price of $413.98, which is higher than its 52-week low but below the new target set by BTIG. The stock has shown resilience with a revenue growth rate of 37.7% year-over-year, although it currently operates with a net margin of -7.1%.

Recent Earnings

Natera reported trailing twelve-month revenue of about $2.71 billion, showing strong growth. However, it has a net margin of -7.1% and a return on equity (ROE) of -12.5%. The next earnings report is scheduled for November 5, 2026, which will provide further insights into the company's performance.

Insider Buying and Selling at Natera, Inc.

Matthew Rabinowitz, an officer and director, sold 50,000 shares on September 11, 2026, valued at approximately $16.4 million, and another 102,000 shares on September 15, 2026, worth about $34.8 million. Jonathan Sheena, a director, also sold 3,150 shares on October 21, 2026, for around $1.29 million under a planned transaction.

Analysts Set New Price Targets

On October 27, 2026, BTIG maintained a Buy rating on Natera with a price target of $430, up from $320. Other analysts, like Morgan Stanley and TD Cowen, have also maintained their bullish outlooks, with targets of $435 and $480, respectively.

About Natera, Inc.

Natera, Inc. is a diagnostics company based in Austin, Texas, specializing in molecular testing services worldwide. It offers various tests for cancer monitoring and genetic screening, making it a key player in the healthcare diagnostics industry.

Bottom Line

Investors should keep an eye on Natera's upcoming earnings report on November 5, 2026, which could provide more clarity on its growth trajectory. With the recent price target increase from BTIG, the market will be watching how the stock performs in the coming days.